Erratum: Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects (BMC Cancer (2013) 14 (48) DOI: 10.1186/1471-2407-14-48);Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Tian, Hongwei ^a   Shi, Gang ^a   Yang, Guoyou ^a   Zhang, Junfeng ^a   Li, Yiming ^a   Du, Tao ^a   Wang, Jianzhou ^a   Xu, Fen ^a   Cheng, Lin ^a   Zhang, Xiaomei ^a   Dai, Lei ^a   Chen, Xiaolei ^a   Zhang, Shuang ^a   Yang, Yang ^a   Yu, Dechao ^a   Wei, Yuquan ^a   Deng, Hongxin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Apoptosis; Cancer immunotherapy; Cell vaccine; GM CSF; IL 18

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHROMIUM 51; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INACTIVATED VACCINE; INTERLEUKIN 18; LIPOSOME; PLASMID VECTOR; TUMOR CELL VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; DRUG CYTOTOXICITY; FEMALE; GENE DELIVERY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; IRRADIATION; LEWIS CARCINOMA; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; RADIATION DOSE; SPLEEN CELL; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY;

ANIMALS; APOPTOSIS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENETIC THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNIZATION; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-18; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; SPLEEN; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 84896731127     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-020-6544-x     Document Type: Erratum

References (48)

1. Jemal A, Ma J, Rosenberg PS, Siegel R, Anderson WF. Increasing lung cancer death rates among young women in Southern and Midwestern states. J Clin Oncol 2012, 30(22):2739-2744. 10.1200/JCO.2012.42.6098, 3402885, 22734032.
2. Laheru D, Biedrzycki B, Thomas AM, Jaffee EM. Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. Pancreatic Cancer 2005, 103:299-327. Humana Press, Columbia University.
3. Maki RG, Livingston PO, Lewis JJ, Janetzki S, Klimstra D, DeSantis D, Srivastava PK, Brennan MF. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci 2007, 52(8):1964-1972. 10.1007/s10620-006-9205-2, 17420942.
4. Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O'Day SJ, Boasberg PD, Stern SL, Ye X, Morton DL. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002, 20(23):4549-4554. 10.1200/JCO.2002.01.151, 12454111.
5. Morton DL, Hsueh EC, Essner R, Foshag LJ, O'Day SJ, Bilchik A, Gupta RK, Hoon DS, Ravindranath M, Nizze JA. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002, 236(4):438. 10.1097/00000658-200210000-00006, 1422598, 12368672.
6. Copier J, Dalgleish A. Whole-cell vaccines: A failure or a success waiting to happen. Curr Opin Mol Ther 2010, 12(1):14.
7. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol 1999, 17(3):1047-1047.
8. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Sci Signal 2011, 331(6024):1565.
9. Fearon ER, Itaya T, Hunt B, Vogelstein B, Frost P. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res 1988, 48(11):2975-2980.
10. Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 1996, 173(2):230-235. 10.1006/cimm.1996.0272, 8912881.
11. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003, 73(2):213-224. 10.1189/jlb.0602313, 12554798.
12. Nagai H, Hara I, Horikawa T, Oka M, Kamidono S, Ichihashi M. Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation. J Invest Dermatol 2002, 119(3):541-548. 10.1046/j.1523-1747.2002.01866.x, 12230493.
13. Tanaka F, Hashimoto W, Robbins P, Lotze M, Tahara H. Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18. Gene Ther 2002, 9(21):1480-1486. 10.1038/sj.gt.3301827, 12378411.
14. Yoshimura K, Hazama S, Iizuka N, Yoshino S, Yamamoto K, Muraguchi M, Ohmoto Y, Noma T, Oka M. Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence. Cancer Gene Ther 2001, 8(1):9.
15. Choi I, Lee J, Zhang S, Park J, Lee K, Sonn C, Yun C. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα. Gene Ther 2011, 18(9):898-909. 10.1038/gt.2011.37, 3169807, 21451575.
16. Wang J, Kobayashi E, Murakami T, KOBAYASHI Y, Sato A. Synergistic anti-tumor effect by combinatorial gene-gun therapy using IL-23 and IL-18 cDNA. J Dermatol Sci 2004, 36(1):66-68. 10.1016/j.jdermsci.2004.08.001, 15488709.
17. Tse BW-C, Russell PJ, Lochner M, Förster I, Power CA. IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. PLoS One 2011, 6(9):e24241. 10.1371/journal.pone.0024241, 3174151, 21935389.
18. Lee H-R, Yoon SY, Song SB, Park Y, Kim TS, Kim S, Hur DY, Song HK, Park H, Cho D. Interleukin-18-mediated interferon-gamma secretion is regulated by thymosin beta 4 in human NK cells. Immunobiology 2011, 216(10):1155-1162. 10.1016/j.imbio.2011.04.002, 21742406.
19. Ye Z-B, Ma T, Li H, Jin XL, Xu HM. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol 2007, 13(11):1747.
20. Ward JE, McNeel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Drug Evaluation 2007, 7(12):1893-1902.
21. Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev 2008, 222(1):287-298. 10.1111/j.1600-065X.2008.00618.x, 18364009.
22. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001, 19(1):145-156.
23. Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan M, Pandha H. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005, 11(12):4469-4478. 10.1158/1078-0432.CCR-04-2337, 15958632.
24. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 2006, 12(11):3394-3401. 10.1158/1078-0432.CCR-06-0145, 16740763.
25. Parekh K, Ramachandran S, Cooper J, Bigner D, Patterson A, Mohanakumar T. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. Lung Cancer 2005, 47(1):17-29. 10.1016/j.lungcan.2004.05.016, 15603851.
26. Deng H, Jiang Q, Yang Y, Zhang S, Ma Y, Xie G, Chen X, Qian Z, Wen Y, Li J. Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma. Cancer Biol Ther 2011, 11(4):401-409. 10.4161/cbt.11.4.14178, 21150280.
27. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003, 21(17):3343-3350. 10.1200/JCO.2003.07.005, 12947071.
28. Heo DS, Park J-G, Hata K, Day R, Herberman RB, Whiteside TL. Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res 1990, 50(12):3681-3690.
29. Asada H, Kishida T, Hirai H, Satoh E, Ohashi S, Takeuchi M, Kubo T, Kita M, Iwakura Y, Imanishi J. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Mol Ther 2002, 5(5):609-616. 10.1006/mthe.2002.0587, 11991752.
30. Matsui M, Moriya O, Belladonna ML, Kamiya S, Lemonnier FA, Yoshimoto T, Akatsuka T. Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A* 0201 transgenic mice. J Virol 2004, 78(17):9093-9104. 10.1128/JVI.78.17.9093-9104.2004, 506963, 15308705.
31. Horton HM, Anderson D, Hernandez P, Barnhart KM, Norman JA, Parker SE. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon α. Proc Natl Acad Sci USA 1999, 96(4):1553-1558. 10.1073/pnas.96.4.1553, 15514, 9990062.
32. Wei Y-Q, Huang M-J, Yang L, Zhao X, Tian L, Lu Y, Shu J-M, Lu C-J, Niu T, Kang B. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 2001, 98(20):11545-11550. 10.1073/pnas.191112198, 58766, 11553767.
33. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21(2):137-148. 10.1016/j.immuni.2004.07.017, 15308095.
34. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of " tumor escape" phenotypes. Nat Immunol 2002, 3(11):999-1005. 10.1038/ni1102-999, 1508168, 12407407.
35. Addison C, Bramson J, Hitt M, Muller W, Gauldie J, Graham F. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther 1998, 5(10):1400. 10.1038/sj.gt.3300731, 9930346.
36. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002, 188(1):147-154. 10.1034/j.1600-065X.2002.18813.x, 12445288.
37. Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E. Tumor necrosis factor α as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007, 25(29):4542-4549. 10.1200/JCO.2007.11.2136, 17925549.
38. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, Balkwill F. The inflammatory cytokine tumor necrosis factor-α generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007, 67(2):585-592. 10.1158/0008-5472.CAN-06-2941, 2679985, 17234767.
39. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C, Mukaida N. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008, 118(2):560. 2213370, 18219394.
40. Egberts J-H, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, Kettler B, von Forstner C, Kneitz C, Tepel J. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2008, 68(5):1443-1450. 10.1158/0008-5472.CAN-07-5704, 18316608.
41. Li B, Vincent A, Cates J, Brantley-Sieders DM, Polk DB, Young PP. Low levels of tumor necrosis factor α increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res 2009, 69(1):338-348. 10.1158/0008-5472.CAN-08-1565, 2651676, 19118019.
42. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukocyte Biol 1998, 64(3):275-290.
43. Moore KW, de Waal Malefyt R, Coffman RL, OGarra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19(1):683-765. 10.1146/annurev.immunol.19.1.683, 11244051.
44. Kang SS, Allen PM. Priming in the presence of IL-10 results in direct enhancement of CD8+ T cell primary responses and inhibition of secondary responses. J Immunol 2005, 174(9):5382-5389.
45. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006, 12(11):1301-1309. 10.1038/nm1492, 2535582, 17041596.
46. Vicari AP, Chiodoni C, Vaure C, Aït-Yahia S, Dercamp C, Matsos F, Reynard O, Taverne C, Merle P, Colombo MP. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002, 196(4):541-549. 10.1084/jem.20020732, 2196048, 12186845.
47. Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, Blaisdell S, Basham B, Dai J, Grein J. IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell 2011, 20(6):781-796. 10.1016/j.ccr.2011.11.003, 22172723.
48. Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G. IL-18 Induces PD-1-Dependent Immunosuppression in Cancer. Cancer Res 2011, 71(16):5393-5399. 10.1158/0008-5472.CAN-11-0993, 21724589.